Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer develops Eyetech's Macugen

Executive Summary

Pfizer and Eyetech Pharmaceuticals (develops drugs to reduce and prevent vision loss caused by eye disease) will jointly develop and commercialize Eyetech's Macugen (pegaptanib sodium) for treating age-related macular degeneration (AMD) and diabetic macular edema (DME).
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Includes Contract
    • Product or Technology Swap

Related Companies

Advertisement
UsernamePublicRestriction

Register